Healthy Extracts Inc. (HYEX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Healthy Extracts Inc. (HYEX) trades at $1.35. Healthy Extracts Inc. focuses on developing and distributing plant-based nutraceuticals targeting heart, brain, and immune health. Market cap: $19.9M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for HYEX: HYEX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HYEX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on HYEX.
How is this calculated? →Healthy Extracts Inc. (HYEX) Healthcare & Pipeline Overview
Healthy Extracts Inc. is a nutraceutical company specializing in plant-based supplements for heart, brain, and immune health, operating in the competitive U.S. market. With a focus on patented products and two business segments, the company aims to capture a growing share of the health supplements market.
What Is the Investment Thesis for HYEX?
Healthy Extracts Inc. presents a speculative investment opportunity within the nutraceuticals market. The company's focus on patented, plant-based products targeting key health areas like heart and brain health could drive growth. Key value drivers include successful commercialization of its neuro-products and expansion of its bergamot-based heart health line. However, the company's negative profit margin of -32.7% and ROE of -9.4% raise concerns about financial sustainability. The high debt-to-equity ratio of 5.10 also warrants caution. Investors should closely monitor the company's ability to improve profitability and manage its debt while capitalizing on growth opportunities in the nutraceuticals market.
Based on FMP financials and quantitative analysis
HYEX Key Highlights
Market Cap of $19.9M reflects its small size within the nutraceuticals industry.
- P/E ratio of 18.08 indicates the stock is trading at a premium relative to its earnings, requiring careful evaluation.
- Gross Margin of 52.4% suggests a strong ability to control production costs, contributing to potential profitability.
- Debt/Equity ratio of 5.10 indicates a high level of financial leverage, which could pose risks if the company faces financial difficulties.
- Beta of -1.24 suggests the stock price is negatively correlated with the market, potentially offering diversification benefits.
Who Are HYEX's Competitors?
HYEX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NUTR NUSATRIP Inc | $41.80 | +0.00% | $628M | 59 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HYEX's Key Strengths?
Proprietary and patented products.
- Focus on plant-based nutraceuticals.
- Targeted approach to heart, brain, and immune health.
- Presence in the growing nutraceuticals market.
What Are HYEX's Weaknesses?
Small market capitalization.
- Negative profit margin and ROE.
- High debt-to-equity ratio.
- Limited brand recognition compared to larger competitors.
What Could Drive HYEX Stock Higher?
Potential FDA approval for new nutraceutical products could drive significant revenue growth.
- Increasing consumer awareness of brain health and demand for cognitive enhancement supplements.
- Expansion of distribution channels through partnerships with retailers and healthcare providers.
- Positive results from clinical trials validating the efficacy of the company's products.
- Launch of new personalized nutrition solutions tailored to individual health needs.
What Are the Key Risks for HYEX?
Financial-distress signal — its Altman Z-Score of 0.14 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-3.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger, more established nutraceutical companies.
- Regulatory changes and compliance requirements could increase operating costs.
- Patent expiration and generic competition could erode market share.
- Negative profit margin and high debt levels raise concerns about financial sustainability.
- Fluctuations in raw material costs could impact profitability.
What Are the Growth Opportunities for HYEX?
- Expansion of Neuro-Product Line: The market for brain health supplements is growing, driven by an aging population and increasing awareness of cognitive health. Healthy Extracts can capitalize on this trend by expanding its line of plant-based neuro-products targeting memory, focus, and cognitive function. Successful product launches and effective marketing could significantly increase revenue in this segment.
- Strategic Partnerships and Distribution Agreements: Partnering with established retailers, distributors, or healthcare providers can significantly expand Healthy Extracts' market reach and brand awareness. These partnerships can provide access to new customer segments and distribution channels, accelerating revenue growth. The timeline for establishing these partnerships can vary, but successful agreements could lead to immediate increases in sales volume and market penetration. This strategy can reduce reliance on direct-to-consumer sales and build a stronger market presence.
- International Market Expansion: While currently focused on the U.S. market, Healthy Extracts can explore opportunities to expand its sales and distribution to international markets. This could involve adapting its product formulations to meet local regulations and consumer preferences. The global nutraceuticals market is vast, and successful international expansion could significantly increase the company's long-term growth potential. The timeline for international expansion would depend on regulatory approvals and market research, but it represents a significant long-term growth opportunity.
- Focus on Scientific Validation and Clinical Trials: Investing in scientific research and clinical trials to validate the efficacy of its products can enhance Healthy Extracts' credibility and attract health-conscious consumers. Positive clinical trial results can be used in marketing materials and to differentiate the company's products from competitors. This strategy can build trust and loyalty among consumers and healthcare professionals, driving sales growth. The timeline for conducting clinical trials can be lengthy, but the long-term benefits in terms of brand reputation and market share can be substantial.
- Development of Personalized Nutrition Solutions: The trend towards personalized nutrition is growing, with consumers seeking tailored health solutions based on their individual needs and preferences. Healthy Extracts can explore opportunities to develop personalized nutrition solutions based on its existing product line and scientific expertise. This could involve offering customized supplement recommendations based on individual health profiles or developing new products tailored to specific health conditions. This strategy can differentiate the company from competitors and attract a loyal customer base.
What Are HYEX's Competitive Advantages?
- Patented formulations provide a degree of exclusivity.
- Focus on plant-based ingredients appeals to a growing market segment.
- Proprietary neuro-products offer a unique value proposition.
What Does HYEX Do?
Healthy Extracts Inc., formerly Grey Cloak Tech Inc., was incorporated in 2014 and rebranded in October 2020 to reflect its focus on health-related products. The company is headquartered in Henderson, Nevada, and operates through two segments: Corporate and Health Supplements. Healthy Extracts focuses on acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals in the United States. Their product line includes heart and immune health products, featuring bergamot-based formulations available in tablet and capsule forms. Additionally, they offer plant-based neuro-products designed to improve brain health, targeting memory, cognition, focus, and neuro-energy. The company's proprietary and patented products are central to its business strategy, aiming to establish a strong position within the nutraceuticals market by addressing key areas such as heart, brain, and immune health.
What Products and Services Does HYEX Offer?
- Acquires and develops plant-based nutraceuticals.
- Patents and markets its proprietary health products.
- Distributes nutraceuticals in the United States.
- Offers heart and immune health products with bergamot.
- Provides neuro-products to improve brain health.
- Operates through Corporate and Health Supplements segments.
How Does HYEX Make Money?
- Develops and patents plant-based nutraceutical formulations.
- Markets and distributes products directly to consumers and through retail channels.
- Generates revenue through the sale of its health supplements.
What Industry Does HYEX Operate In?
Healthy Extracts Inc. operates in the growing nutraceuticals market, driven by increasing consumer interest in preventative healthcare and natural health solutions. The market is characterized by intense competition from both large pharmaceutical companies and smaller, specialized nutraceutical firms. Key trends include a focus on plant-based ingredients, personalized nutrition, and scientific validation of product efficacy. Healthy Extracts aims to differentiate itself through patented formulations and targeted health benefits, but faces challenges in gaining market share against established players with greater resources and brand recognition.
Who Are HYEX's Key Customers?
- Health-conscious consumers seeking natural supplements.
- Individuals looking to improve heart, brain, and immune health.
- Customers interested in plant-based alternatives to traditional medications.
Company Profile
Healthy Extracts Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Henderson, US. The company is led by CEO Donald Swanson. HYEX has traded publicly since 2015.
How Healthy Extracts Inc. Is Valued
Healthy Extracts Inc. carries a market capitalization of $19.9M, placing it in the micro-cap category.
Key Financial Metrics
Return on equity for Healthy Extracts Inc. stands at -3.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -2.5%, showing how much profit it generates from its asset base. Its free cash flow yield is 3.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.69 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -1.9%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Healthy Extracts Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.14 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Healthy Extracts Inc. revenue of about $14.1M for fiscal 2026, with EPS near $0.13.
Insider Activity
The most recent 10 insider filings for Healthy Extracts Inc. break down as 2 sales and 8 purchases. On net that is roughly 18.5M shares acquired (about $307763.4B) — insiders putting money in tends to read as conviction.
HYEX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary and patented products.
- Focus on plant-based nutraceuticals.
- Targeted approach to heart, brain, and immune health.
- Presence in the growing nutraceuticals market.
Bear Case
- Small market capitalization.
- Negative profit margin and ROE.
- High debt-to-equity ratio.
- Limited brand recognition compared to larger competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
HYEX Latest News
No recent news available for HYEX.
HYEX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HYEX.
Price Targets
Wall Street price target analysis for HYEX.
HYEX MoonshotScore
What does this score mean?
The MoonshotScore rates HYEX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
HYEX OTC Market Information
The OTCQB Venture Market is the middle tier of the over-the-counter (OTC) market, providing a stepping stone for companies aiming to eventually list on a major exchange like the NYSE or NASDAQ. Companies on the OTCQB must meet certain financial reporting standards, undergo annual verification, and maintain a minimum bid price, offering more transparency compared to the lower OTC Pink tier. Listing on OTCQB can improve a company's visibility and attract a broader range of investors compared to the Pink market, but it still carries more risk than exchange-listed stocks.
- OTC Tier: OTC Other
- Lower liquidity compared to exchange-listed stocks.
- Less stringent regulatory oversight.
- Potential for wider bid-ask spreads.
- Increased price volatility.
- Higher risk of fraud or manipulation.
- Verify the company's financial statements and SEC filings.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Understand the OTCQB listing requirements and disclosure obligations.
- Monitor the company's trading volume and price volatility.
- Consult with a financial advisor before investing.
- OTCQB listing indicates a higher level of compliance compared to OTC Pink.
- Current financial disclosure provides some transparency.
- Company's focus on patented products suggests a degree of innovation.
- Operating history since 2014 provides some track record.
- Company's headquarters in the United States.
HYEX Healthcare Stock FAQ
What does Healthy Extracts Inc. do?
Healthy Extracts Inc. is a nutraceutical company that develops, patents, markets, and distributes plant-based supplements. It operates in two segments: Corporate and Health Supplements. The company's products target key health areas such as heart, brain, and immune health. They offer bergamot-based products for heart and immune support, as well as plant-based neuro-products designed to improve cognitive function, memory, and focus.
What do analysts say about HYEX stock?
As of 2026-03-16, there is no available analyst coverage for Healthy Extracts Inc. (HYEX). Given its small market capitalization and OTCQB listing, the company may not be widely followed by analysts. Investors should conduct their own thorough research and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key metrics to monitor include revenue growth, profitability, and cash flow.
What are the main risks for HYEX?
Healthy Extracts Inc. faces several risks, including intense competition in the nutraceuticals market, regulatory challenges, and potential patent expiration. The company's small size and limited resources make it vulnerable to competition from larger, more established players. Regulatory changes and compliance requirements could increase operating costs and delay product launches. Patent expiration could lead to generic competition and erode market share.
How does Healthy Extracts Inc. navigate regulatory approval processes?
As a nutraceutical company, Healthy Extracts Inc. is subject to regulations from the Food and Drug Administration (FDA) regarding the safety and labeling of its products. While nutraceuticals do not require the same pre-market approval as pharmaceuticals, the company must ensure its products comply with FDA regulations and avoid making unsubstantiated health claims.
How does Healthy Extracts Inc. manage patent expiration risks?
Healthy Extracts Inc. relies on patents to protect its proprietary formulations and maintain a competitive advantage. However, patents eventually expire, which could lead to generic competition and erode market share. To mitigate this risk, the company must continuously innovate and develop new products with patentable features.
What are the key factors to evaluate for HYEX?
Evaluate HYEX on fundamentals, analyst consensus, and risk factors. Healthy Extracts Inc. presents a speculative investment opportunity within the nutraceuticals market. Not financial advice.
How frequently does HYEX data refresh on this page?
HYEX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HYEX's recent stock price performance?
Healthy Extracts Inc. (HYEX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary and patented products. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage impacts the depth of available insights.
- OTC market carries inherent risks due to lower liquidity and regulatory oversight.